» Articles » PMID: 36467049

Exploring the Potential Mechanism of Fritiliariae Irrhosae Bulbus on Ischemic Stroke Based on Network Pharmacology and Experimental Validation

Overview
Journal Front Pharmacol
Date 2022 Dec 5
PMID 36467049
Authors
Affiliations
Soon will be listed here.
Abstract

To study the potential targets and molecular mechanisms of Fritiliariae Irrhosae Bulbus (FIB) in the treatment of ischemic strokes based on a network pharmacology strategy, with a combination of molecular docking and animal experiments. The active components and targets of FIB were screened by TCMSP database and TCMIP database, and the related targets of ischemic strokes were screened by GeneCards, OMIM, CTD, and DrugBank, then the intersection targets of the two were taken. The protein interaction network was constructed by STRING, the PPI network diagram was drawn by using Cytoscape software, and the key targets of FIB treatment of ischemic strokes were analyzed by MCODE. The DAVID database was used for GO and KEGG enrichment analysis, and the potential pathway of FIB against ischemic strokes was obtained. Molecular docking was performed by using AutoDock Tools 1.5.6 software. Finally, a mouse model of ischemic stroke was established, and the results of network pharmacology were verified by experiments. Realtime Polymerase Chain Reaction was used to detect the expression levels of relevant mRNAs in the mouse brain tissue. Western blot was used to detect the expression levels of related proteins in the mouse brain tissue. 13 kinds of active components of FIB were screened, 31 targets were found in the intersection of FIB and ischemic strokes, 10 key targets were obtained by MCODE analysis, 236 biological processes were involved in GO enrichment analysis, and key targets of KEGG enrichment analysis were mainly concentrated in Neuroactive light receptor interaction, Calcium signaling pathway, Cholinergic synapse, Hepatitis B, Apoptosis-multiple specifications, Pathways in cancer and other significantly related pathways. There was good binding activity between the screened main active components and target proteins when molecular docking was performed. Animal experiments showed that the infarct volume of brain tissue in the FIB treatment group was considerably reduced. RT-qPCR and the results of Western Blot showed that FIB could inhibit the expression of active-Caspase3, HSP90AA1, phosphorylated C-JUN, and COX2. Based on network pharmacology, the effect of FIB in the treatment of ischemic strokes was discussed through the multi-component-multi-target-multi-pathway. The therapeutic effect and potential mechanisms of FIB on ischemic strokes were preliminarily explored, which provided a ground work for further researches on the pharmacodynamic material basis, mechanism of action and clinical application.

Citing Articles

Investigation into the Potential Mechanism of Radix Paeoniae Rubra Against Ischemic Stroke Based on Network Pharmacology.

Wen T, Xin G, Zhou Q, Wang T, Yu X, Li Y Nutrients. 2025; 16(24.

PMID: 39771032 PMC: 11678013. DOI: 10.3390/nu16244409.


Long non-coding RNA SNHG12 regulates leptomeningeal collateral remodeling via RGMa after ischemic stroke.

Jiang A, Wang Z, Cheng R, Zhang S, Wu Q, Qin X Neurotherapeutics. 2024; 21(5):e00429.

PMID: 39138027 PMC: 11579872. DOI: 10.1016/j.neurot.2024.e00429.

References
1.
Khan S, Lee T . Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. Front Pharmacol. 2022; 13:968148. PMC: 9358010. DOI: 10.3389/fphar.2022.968148. View

2.
Huang Y, Chen S, Luo Y, Han Z . Crosstalk between Inflammation and the BBB in Stroke. Curr Neuropharmacol. 2020; 18(12):1227-1236. PMC: 7770647. DOI: 10.2174/1570159X18666200620230321. View

3.
Uzdensky A . Apoptosis regulation in the penumbra after ischemic stroke: expression of pro- and antiapoptotic proteins. Apoptosis. 2019; 24(9-10):687-702. DOI: 10.1007/s10495-019-01556-6. View

4.
Grosser T, Fries S, FitzGerald G . Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006; 116(1):4-15. PMC: 1323269. DOI: 10.1172/JCI27291. View

5.
Zhou Z, Lu J, Liu W, Manaenko A, Hou X, Mei Q . Advances in stroke pharmacology. Pharmacol Ther. 2018; 191:23-42. DOI: 10.1016/j.pharmthera.2018.05.012. View